Neu­ro­science biotech led by for­mer Pfiz­er crew wins $17M to tar­get tox­ic tau

With big phar­ma play­ers march­ing out of the dis­as­ter-prone field of neu­ro­sciences one-by-one, small biotechs are pick­ing up the tab.

Cam­bridge, Mass­a­chu­setts-based Pin­teon Ther­a­peu­tics …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER